Free Trial

Sana Biotechnology (SANA) Financials

Sana Biotechnology logo
$2.00 +0.01 (+0.50%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$2.06 +0.06 (+3.00%)
As of 04:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Sana Biotechnology

Annual Income Statements for Sana Biotechnology

This table shows Sana Biotechnology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders
-267 -283 -269
Consolidated Net Income / (Loss)
-267 -283 -269
Net Income / (Loss) Continuing Operations
-267 -283 -269
Total Pre-Tax Income
-267 -283 -269
Total Operating Income
-273 -293 -273
Total Gross Profit
0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00
Total Operating Expenses
273 293 273
Selling, General & Admin Expense
64 73 72
Research & Development Expense
209 220 201
Total Other Income / (Expense), net
5.96 9.89 3.09
Interest & Investment Income
10 9.94 3.76
Other Income / (Expense), net
-4.51 -0.05 -0.67
Basic Earnings per Share
($1.16) ($1.46) ($1.43)
Weighted Average Basic Shares Outstanding
230.89M 194.54M 188.34M
Diluted Earnings per Share
($1.16) ($1.46) ($1.43)
Weighted Average Diluted Shares Outstanding
230.89M 194.54M 188.34M
Weighted Average Basic & Diluted Shares Outstanding
225.02M 220.45M 191.36M

Quarterly Income Statements for Sana Biotechnology

This table shows Sana Biotechnology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
-49 -60 -50 -107 -88 0.98 -114 -82 -80 -85
Consolidated Net Income / (Loss)
-49 -60 -50 -107 -88 0.98 -114 -82 -80 -85
Net Income / (Loss) Continuing Operations
-49 -60 -50 -107 -88 0.98 -114 -82 -80 -85
Total Pre-Tax Income
-49 -60 -50 -107 -88 0.98 -114 -82 -80 -85
Total Operating Income
-51 -62 -49 -111 -91 -2.18 -116 -84 -82 -86
Total Operating Expenses
51 62 49 111 91 2.18 116 84 82 86
Selling, General & Admin Expense
17 14 16 16 21 19 17 17 23 16
Research & Development Expense
34 48 33 94 70 -17 100 67 58 71
Total Other Income / (Expense), net
1.80 1.84 -0.92 3.25 2.46 3.17 2.29 1.98 1.35 1.07
Interest & Investment Income
1.66 2.58 3.20 3.03 2.73 2.86 2.37 1.98 1.61 1.17
Other Income / (Expense), net
0.14 -0.74 -4.12 0.22 - 0.30 -0.08 - -0.27 -0.11
Basic Earnings per Share
($0.21) ($0.25) ($0.21) ($0.49) ($0.44) $0.00 ($0.59) ($0.43) ($0.42) ($0.45)
Weighted Average Basic Shares Outstanding
230.89M 235.41M 234.44M 217.29M 194.54M 196.98M 192.54M 191.23M 188.34M 189.30M
Diluted Earnings per Share
($0.21) ($0.25) ($0.21) ($0.49) ($0.44) $0.00 ($0.59) ($0.43) ($0.42) ($0.45)
Weighted Average Diluted Shares Outstanding
230.89M 235.41M 234.44M 217.29M 194.54M 200.47M 192.54M 191.23M 188.34M 189.30M
Weighted Average Basic & Diluted Shares Outstanding
225.02M 223.27M 222.47M 221.50M 220.45M 197.13M 196.94M 191.50M 191.36M 190.73M

Annual Cash Flow Statements for Sana Biotechnology

This table details how cash moves in and out of Sana Biotechnology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents
-5.95 -50 -75
Net Cash From Operating Activities
-223 -254 -290
Net Cash From Continuing Operating Activities
-223 -254 -290
Net Income / (Loss) Continuing Operations
-267 -283 -269
Consolidated Net Income / (Loss)
-267 -283 -269
Depreciation Expense
17 25 16
Non-Cash Adjustments To Reconcile Net Income
36 35 41
Changes in Operating Assets and Liabilities, net
-10 -30 -77
Net Cash From Investing Activities
17 172 211
Net Cash From Continuing Investing Activities
17 172 211
Purchase of Property, Plant & Equipment
-33 -20 -21
Purchase of Investments
-226 -158 -79
Sale and/or Maturity of Investments
277 350 310
Other Investing Activities, net
0.00 0.00 0.00
Net Cash From Financing Activities
200 32 4.91
Net Cash From Continuing Financing Activities
200 32 4.91
Issuance of Common Equity
192 32 4.91
Other Financing Activities, net
7.74 0.00 0.00

Quarterly Cash Flow Statements for Sana Biotechnology

This table details how cash moves in and out of Sana Biotechnology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
0.57 -7.96 -42 44 -35 -12 13 -16 13 -31
Net Cash From Operating Activities
-47 -52 -59 -66 -52 -64 -59 -79 -76 -65
Net Cash From Continuing Operating Activities
-47 -52 -59 -66 -52 -64 -59 -79 -76 -65
Net Income / (Loss) Continuing Operations
-49 -60 -50 -107 -88 0.98 -114 -82 -80 -85
Consolidated Net Income / (Loss)
-49 -60 -50 -107 -88 0.98 -114 -82 -80 -85
Depreciation Expense
5.69 4.06 3.90 3.75 11 4.50 4.45 4.35 4.20 4.02
Non-Cash Adjustments To Reconcile Net Income
5.39 9.89 13 7.55 7.82 8.41 10 9.19 11 10
Changes in Operating Assets and Liabilities, net
-9.18 -5.84 -26 31 17 -77 41 -11 -11 6.01
Net Cash From Investing Activities
47 42 5.82 -77 15 51 43 63 88 32
Net Cash From Continuing Investing Activities
47 42 5.82 -77 15 51 43 63 88 32
Purchase of Property, Plant & Equipment
-0.44 -4.09 -13 -16 -14 -2.23 -1.58 -2.18 -4.60 -4.35
Purchase of Investments
-13 -36 -63 -114 -26 -60 -51 -20 -15 -18
Sale and/or Maturity of Investments
61 82 81 53 55 114 95 85 108 54
Net Cash From Financing Activities
0.64 2.08 11 186 1.72 0.19 30 0.24 1.06 1.62
Net Cash From Continuing Financing Activities
0.64 2.08 11 186 1.72 0.19 30 0.24 1.06 1.62
Issuance of Common Equity
0.70 1.91 3.00 186 1.72 0.19 30 0.24 1.06 1.62
Other Financing Activities, net
-0.06 0.17 - - - - - - - -

Annual Balance Sheets for Sana Biotechnology

This table presents Sana Biotechnology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets
501 565 823
Total Current Assets
161 214 444
Cash & Equivalents
128 134 177
Restricted Cash
3.83 3.83 6.10
Short-Term Investments
25 72 247
Prepaid Expenses
4.48 4.49 14
Plant, Property, & Equipment, net
77 71 67
Total Noncurrent Assets
263 281 311
Long-Term Investments
0.00 0.00 10
Goodwill
141 141 141
Intangible Assets
59 59 59
Other Noncurrent Operating Assets
63 81 101
Total Liabilities & Shareholders' Equity
501 565 823
Total Liabilities
251 278 323
Total Current Liabilities
45 64 112
Short-Term Debt
0.00 0.00 55
Accounts Payable
5.21 4.11 2.86
Accrued Expenses
13 23 15
Current Employee Benefit Liabilities
14 24 26
Other Current Liabilities
13 13 12
Total Noncurrent Liabilities
205 213 212
Capital Lease Obligations
82 91 96
Other Noncurrent Operating Liabilities
123 122 116
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
251 288 499
Total Preferred & Common Equity
251 288 499
Preferred Stock
0.00 0.00 0.00
Total Common Equity
251 288 499
Common Stock
1,855 1,626 1,558
Retained Earnings
-1,605 -1,338 -1,055
Accumulated Other Comprehensive Income / (Loss)
0.01 -0.06 -4.33

Quarterly Balance Sheets for Sana Biotechnology

This table presents Sana Biotechnology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
559 619 681 631 707 747 898
Total Current Assets
210 263 321 280 339 370 500
Cash & Equivalents
127 135 177 168 174 160 163
Restricted Cash
3.83 3.83 3.83 3.83 6.10 6.10 6.10
Short-Term Investments
72 117 134 100 152 189 322
Prepaid Expenses
7.31 7.98 6.35 7.12 6.61 15 8.40
Plant, Property, & Equipment, net
83 86 82 68 63 64 67
Total Noncurrent Assets
266 269 278 284 306 313 331
Long-Term Investments
0.00 0.00 0.00 0.00 0.00 10 30
Goodwill
141 141 141 141 141 141 141
Intangible Assets
59 59 59 59 59 59 59
Other Noncurrent Operating Assets
67 69 79 84 106 103 100
Total Liabilities & Shareholders' Equity
559 619 681 631 707 747 898
Total Liabilities
267 279 306 266 352 319 332
Total Current Liabilities
47 51 53 67 112 103 115
Short-Term Debt
0.00 0.00 0.00 0.00 58 57 59
Accounts Payable
2.99 3.82 6.10 9.93 3.09 2.33 3.99
Accrued Expenses
15 21 20 19 18 13 15
Current Employee Benefit Liabilities
18 16 14 24 20 17 25
Other Current Liabilities
11 10.00 13 13 13 13 12
Total Noncurrent Liabilities
220 228 253 199 240 216 217
Capital Lease Obligations
85 89 93 83 100 102 100
Other Noncurrent Operating Liabilities
134 140 160 116 140 114 117
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
292 340 375 366 355 428 566
Total Preferred & Common Equity
292 340 375 366 355 428 566
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
292 340 375 366 355 428 566
Common Stock
1,848 1,836 1,821 1,616 1,607 1,567 1,547
Retained Earnings
-1,556 -1,496 -1,446 -1,250 -1,251 -1,137 -974
Accumulated Other Comprehensive Income / (Loss)
0.05 -0.02 -0.02 -0.20 -0.87 -2.14 -6.41

Annual Metrics And Ratios for Sana Biotechnology

This table displays calculated financial ratios and metrics derived from Sana Biotechnology's official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics
- - -
Revenue Growth
0.00% 0.00% 0.00%
EBITDA Growth
3.27% -4.28% 25.45%
EBIT Growth
5.44% -7.30% 23.38%
NOPAT Growth
6.97% -7.55% 23.63%
Net Income Growth
5.82% -5.11% 24.29%
EPS Growth
20.55% -2.10% 33.18%
Operating Cash Flow Growth
12.00% 12.57% -15.53%
Free Cash Flow Firm Growth
-20.22% 40.35% 22.71%
Invested Capital Growth
3.81% -19.50% 67.03%
Revenue Q/Q Growth
0.00% 0.00% 0.00%
EBITDA Q/Q Growth
10.25% -0.68% 10.37%
EBIT Q/Q Growth
11.28% -3.12% 9.58%
NOPAT Q/Q Growth
12.72% -3.11% 9.76%
Net Income Q/Q Growth
12.77% -2.78% 10.10%
EPS Q/Q Growth
16.55% -1.39% -13.49%
Operating Cash Flow Q/Q Growth
2.10% 8.68% 10.50%
Free Cash Flow Firm Q/Q Growth
9.06% 4.89% 32.41%
Invested Capital Q/Q Growth
0.41% -4.21% 3.53%
Profitability Metrics
- - -
Gross Margin
0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00%
Interest Burden Percent
96.22% 96.61% 98.62%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00%
Return on Equity (ROE)
-99.17% -72.00% -43.90%
Cash Return on Invested Capital (CROIC)
-114.34% -86.46% -163.64%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-99.17% -72.00% -43.90%
Return on Equity Simple (ROE_SIMPLE)
-106.49% -98.52% -53.97%
Net Operating Profit after Tax (NOPAT)
-191 -205 -191
NOPAT Margin
0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-78.69% -38.35% -17.65%
Return On Investment Capital (ROIC_SIMPLE)
-57.47% -54.23% -29.33%
Cost of Revenue to Revenue
0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-277 -293 -273
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-260 -269 -258
Valuation Ratios
- - -
Price to Book Value (P/BV)
1.45 2.80 1.51
Price to Tangible Book Value (P/TBV)
7.18 9.17 2.52
Price to Revenue (P/Rev)
0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.65 4.05 2.21
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.33 0.32 0.30
Long-Term Debt to Equity
0.33 0.32 0.19
Financial Leverage
-0.36 -0.52 -0.73
Leverage Ratio
1.98 1.76 1.59
Compound Leverage Factor
1.91 1.70 1.57
Debt to Total Capital
24.58% 24.02% 23.24%
Short-Term Debt to Total Capital
0.00% 0.00% 8.51%
Long-Term Debt to Total Capital
24.58% 24.02% 14.74%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
75.42% 75.98% 76.76%
Debt to EBITDA
-0.31 -0.34 -0.59
Net Debt to EBITDA
0.29 0.44 1.12
Long-Term Debt to EBITDA
-0.31 -0.34 -0.37
Debt to NOPAT
-0.43 -0.44 -0.79
Net Debt to NOPAT
0.39 0.58 1.51
Long-Term Debt to NOPAT
-0.43 -0.44 -0.50
Altman Z-Score
-5.16 -2.97 -1.01
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
3.54 3.31 3.99
Quick Ratio
3.36 3.18 3.80
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-197 -164 -275
Operating Cash Flow to CapEx
-667.52% -1,265.88% -1,389.39%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00
Efficiency Ratios
- - -
Asset Turnover
0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00
Capital & Investment Metrics
- - -
Invested Capital
176 169 210
Invested Capital Turnover
0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
6.46 -41 84
Enterprise Value (EV)
289 686 464
Market Capitalization
364 804 753
Book Value per Share
$1.12 $1.46 $2.62
Tangible Book Value per Share
$0.23 $0.44 $1.57
Total Capital
332 378 651
Total Debt
82 91 151
Total Long-Term Debt
82 91 96
Net Debt
-75 -118 -289
Capital Expenditures (CapEx)
33 20 21
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-41 -60 -42
Debt-free Net Working Capital (DFNWC)
115 149 388
Net Working Capital (NWC)
115 149 333
Net Nonoperating Expense (NNE)
76 78 79
Net Nonoperating Obligations (NNO)
-75 -118 -289
Total Depreciation and Amortization (D&A)
17 25 16
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($1.16) ($1.46) ($1.43)
Adjusted Weighted Average Basic Shares Outstanding
230.89M 194.54M 188.34M
Adjusted Diluted Earnings per Share
($1.16) ($1.46) ($1.43)
Adjusted Weighted Average Diluted Shares Outstanding
230.89M 194.54M 188.34M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
225.02M 220.45M 191.36M
Normalized Net Operating Profit after Tax (NOPAT)
-191 -205 -191
Normalized NOPAT Margin
0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00%
Debt Service Ratios
- - -
EBIT to Interest Expense
0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Sana Biotechnology

This table displays calculated financial ratios and metrics derived from Sana Biotechnology's official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
43.25% -2,329.91% 55.69% -33.95% -1.92% 103.19% -61.50% -182.92% 27.68% -2.16%
EBIT Growth
44.02% -3,228.17% 54.03% -31.48% -10.44% 97.82% -59.19% -164.42% 26.07% -3.44%
NOPAT Growth
43.87% -1,882.24% 57.54% -31.73% -10.80% 96.38% -59.51% -165.27% 26.50% -3.30%
Net Income Growth
44.31% -6,189.84% 55.88% -30.87% -9.54% 101.16% -57.32% -161.14% 27.35% -2.23%
EPS Growth
52.27% 0.00% 64.41% -13.95% -4.76% 100.00% -51.28% -152.94% -68.00% 2.17%
Operating Cash Flow Growth
9.23% 18.46% 0.44% 17.21% 31.69% 1.92% 17.74% -2.01% 30.91% -28.34%
Free Cash Flow Firm Growth
-87.73% -271.47% 47.50% 95.03% 84.19% 109.46% 83.19% 14.78% 23.06% -289.05%
Invested Capital Growth
3.81% -0.96% -4.92% -30.84% -19.50% -12.99% -15.22% 132.71% 67.03% 2,634.47%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
22.95% -17.84% 53.54% -34.54% -3,127.66% 102.34% -40.42% -2.37% 5.37% -18.72%
EBIT Q/Q Growth
18.84% -16.84% 51.59% -21.95% -4,725.29% 98.39% -38.45% -2.43% 4.91% -18.04%
NOPAT Q/Q Growth
17.64% -25.09% 55.41% -22.19% -2,808.45% 97.32% -38.35% -2.77% 5.10% -18.22%
Net Income Q/Q Growth
18.11% -19.15% 53.21% -21.97% -9,054.98% 100.86% -38.81% -2.09% 5.49% -17.46%
EPS Q/Q Growth
16.00% -19.05% 57.14% -11.36% 0.00% 100.00% -37.21% -2.38% 6.67% -15.38%
Operating Cash Flow Q/Q Growth
8.99% 11.48% 10.80% -26.32% 18.24% -8.08% 25.82% -4.21% -17.39% 9.35%
Free Cash Flow Firm Q/Q Growth
-1.28% -62.12% -178.37% 58.93% -192.51% 149.64% 73.64% -30.66% 44.68% 11.74%
Invested Capital Q/Q Growth
0.41% 1.38% 12.79% -9.58% -4.21% -2.67% -17.96% 5.25% 3.53% -5.16%
Profitability Metrics
- - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 99.95% 100.00% 100.00% 100.06% 100.00% 100.00%
Interest Burden Percent
96.74% 95.87% 94.01% 97.25% 97.29% -52.40% 97.96% 97.65% 98.03% 98.64%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-99.17% -92.90% -70.51% -76.82% -72.00% -59.15% -72.73% -56.67% -43.90% -42.94%
Cash Return on Invested Capital (CROIC)
-114.34% -123.33% -94.85% -83.06% -86.46% -90.84% -113.75% -223.45% -163.64% -386.63%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-99.17% -92.90% -70.51% -76.82% -72.00% -59.15% -72.73% -56.67% -43.90% -42.94%
Return on Equity Simple (ROE_SIMPLE)
0.00% -104.56% -72.10% -82.26% 0.00% -75.33% -101.87% -74.76% 0.00% -52.96%
Net Operating Profit after Tax (NOPAT)
-36 -43 -35 -78 -63 -2.18 -81 -59 -57 -60
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-13.97% -10.90% -9.25% -13.98% -12.13% 1.15% -10.89% -5.73% -5.20% -4.18%
Return On Investment Capital (ROIC_SIMPLE)
-10.72% - - - -16.76% - - - -8.80% -
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-51 -63 -53 -111 -91 -1.88 -116 -84 -82 -86
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-45 -58 -50 -107 -79 2.62 -112 -80 -78 -82
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
1.45 3.16 3.56 5.88 2.80 2.08 3.21 1.46 1.51 2.02
Price to Tangible Book Value (P/TBV)
7.18 9.99 8.65 12.57 9.17 4.59 7.35 2.74 2.52 3.12
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.65 4.61 6.04 12.94 4.05 3.24 5.33 1.89 2.21 3.83
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.33 0.29 0.26 0.25 0.32 0.23 0.45 0.37 0.30 0.28
Long-Term Debt to Equity
0.33 0.29 0.26 0.25 0.32 0.23 0.28 0.24 0.19 0.18
Financial Leverage
-0.36 -0.47 -0.49 -0.53 -0.52 -0.59 -0.60 -0.72 -0.73 -0.85
Leverage Ratio
1.98 1.81 1.91 1.78 1.76 1.64 1.69 1.59 1.59 1.53
Compound Leverage Factor
1.92 1.73 1.79 1.73 1.72 -0.86 1.65 1.55 1.56 1.51
Debt to Total Capital
24.58% 22.62% 20.68% 19.85% 24.02% 18.56% 30.89% 27.05% 23.24% 21.96%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 11.37% 9.75% 8.51% 8.19%
Long-Term Debt to Total Capital
24.58% 22.62% 20.68% 19.85% 24.02% 18.56% 19.51% 17.31% 14.74% 13.77%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
75.42% 77.38% 79.32% 80.15% 75.98% 81.44% 69.11% 72.95% 76.76% 78.04%
Debt to EBITDA
-0.31 -0.30 -0.39 -0.31 -0.34 -0.31 -0.45 -0.51 -0.59 -0.55
Net Debt to EBITDA
0.29 0.41 0.73 0.75 0.44 0.71 0.49 0.67 1.12 1.26
Long-Term Debt to EBITDA
-0.31 -0.30 -0.39 -0.31 -0.34 -0.31 -0.29 -0.33 -0.37 -0.35
Debt to NOPAT
-0.43 -0.39 -0.50 -0.42 -0.44 -0.42 -0.62 -0.70 -0.79 -0.75
Net Debt to NOPAT
0.39 0.54 0.94 0.99 0.58 0.95 0.67 0.91 1.51 1.72
Long-Term Debt to NOPAT
-0.43 -0.39 -0.50 -0.42 -0.44 -0.42 -0.39 -0.45 -0.50 -0.47
Altman Z-Score
-3.67 -1.83 -0.66 1.29 -1.79 -0.65 -0.69 -0.90 -0.24 0.74
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
3.54 4.47 5.20 6.07 3.31 4.19 3.02 3.60 3.99 4.36
Quick Ratio
3.36 4.23 4.96 5.88 3.18 4.03 2.91 3.40 3.80 4.23
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-42 -42 -26 -9.20 -22 24 -49 -185 -142 -256
Operating Cash Flow to CapEx
-10,816.74% -1,266.04% -448.38% -414.21% -369.92% -2,845.95% -3,728.66% -3,643.01% -1,652.91% -1,489.56%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
176 175 173 153 169 177 182 221 210 203
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
6.46 -1.70 -8.94 -68 -41 -26 -33 126 84 196
Enterprise Value (EV)
289 808 1,042 1,982 686 573 968 419 464 779
Market Capitalization
364 925 1,209 2,204 804 762 1,141 626 753 1,141
Book Value per Share
$1.12 $1.31 $1.53 $1.70 $1.46 $1.86 $1.85 $2.24 $2.62 $2.98
Tangible Book Value per Share
$0.23 $0.42 $0.63 $0.80 $0.44 $0.84 $0.81 $1.19 $1.57 $1.93
Total Capital
332 378 428 468 378 449 514 587 651 725
Total Debt
82 85 89 93 91 83 159 159 151 159
Total Long-Term Debt
82 85 89 93 91 83 100 102 96 100
Net Debt
-75 -117 -167 -222 -118 -189 -173 -207 -289 -363
Capital Expenditures (CapEx)
0.44 4.09 13 16 14 2.23 1.58 2.18 4.60 4.35
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-41 -40 -43 -47 -60 -60 -47 -31 -42 -47
Debt-free Net Working Capital (DFNWC)
115 163 213 268 149 213 285 324 388 445
Net Working Capital (NWC)
115 163 213 268 149 213 227 267 333 385
Net Nonoperating Expense (NNE)
13 17 16 30 25 -3.17 33 23 23 25
Net Nonoperating Obligations (NNO)
-75 -117 -167 -222 -118 -189 -173 -207 -289 -363
Total Depreciation and Amortization (D&A)
5.69 4.06 3.90 3.75 11 4.50 4.45 4.35 4.20 4.02
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.21) ($0.25) ($0.21) ($0.49) ($0.44) $0.00 ($0.59) ($0.43) ($0.42) ($0.45)
Adjusted Weighted Average Basic Shares Outstanding
230.89M 235.41M 234.44M 217.29M 194.54M 196.98M 192.54M 191.23M 188.34M 189.30M
Adjusted Diluted Earnings per Share
($0.21) ($0.25) ($0.21) ($0.49) ($0.44) $0.00 ($0.59) ($0.43) ($0.42) ($0.45)
Adjusted Weighted Average Diluted Shares Outstanding
230.89M 235.41M 234.44M 217.29M 194.54M 200.47M 192.54M 191.23M 188.34M 189.30M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
225.02M 223.27M 222.47M 221.50M 220.45M 197.13M 196.94M 191.50M 191.36M 190.73M
Normalized Net Operating Profit after Tax (NOPAT)
-36 -43 -35 -78 -63 -1.53 -81 -59 -57 -60
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Sana Biotechnology's Financials

When does Sana Biotechnology's fiscal year end?

According to the most recent income statement we have on file, Sana Biotechnology's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Sana Biotechnology's net income changed over the last 2 years?
The last 5 years of Sana Biotechnology's net income performance:
  • 2022: -$269.48 million
  • 2023: -$283.26 million
  • 2024: -$266.76 million
Find out what analysts predict for Sana Biotechnology in the coming months.
What is Sana Biotechnology's operating income?
Sana Biotechnology's total operating income in 2024 was -$272.72 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $272.72 million
How has Sana Biotechnology revenue changed over the last 2 years?

Over the last 2 years, Sana Biotechnology's total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Sana Biotechnology have?

Sana Biotechnology's total liabilities were at $250.52 million at the end of 2024, a 9.8% decrease from 2023, and a 22.5% decrease since 2022.

How much cash does Sana Biotechnology have?

In the past 2 years, Sana Biotechnology's cash and equivalents has ranged from $127.57 million in 2024 to $176.77 million in 2022, and is currently $127.57 million as of their latest financial filing in 2024.

How has Sana Biotechnology's book value per share changed over the last 2 years?

Over the last 2 years, Sana Biotechnology's book value per share changed from 2.62 in 2022 to 1.12 in 2024, a change of -57.1%.



This page (NASDAQ:SANA) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners